DOCSLIB.ORG

Interleukin 1 Can Act As a B-Cell Growth and Differentiation Factor

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Interleukin 1 Can Act As a B-Cell Growth and Differentiation Factor Proc. Nati. Acad. Sci. USA Vol. 82, pp. 8153-8157, December 1985 Immunology Interleukin 1 can act as a B-cell growth and differentiation factor (cytokines/hapten-gelatin fractionation/T-cel-independent antigens/antibody-forming cell dones/enzyme-linked immunosorbent assay) BEVERLEY L. PIKE AND G. J. V. NOSSAL The Walter and Eliza Hall Institute of Medical Research, Post Office, Royal Melbourne Hospital, Victoria 3050, Australia Contributed by G. J. V. Nossal, July 23, 1985 ABSTRACT Splenic B lymphocytes specifically reactive to B cell, the bioactivities exhibited by IL-1 were identical to the hapten fluorescein (FLU) were prepared from nonimmune those in the filler cell-free system. adult mice by affinity fractionation on hapten-gelatin. These FLU-specific B cells were cultured as single cells or in small numbers in 10-ul wells either in the absence of any feeder, MATERIALS AND METHODS filler, or accessory cell or in the presence of 3T3 fibroblasts Mice and Preparation of Fluorescein (FLU)-Specific Splenic acting as filer cells. A selected batch ofa "T-cell-independent" B Cells. Specific-pathogen-free CBA/CaH/Wehi mice were antigen, FLU-Ficoll, which induces growth and differentiation used as spleen donors at 8-10 weeks of age. Hapten-specific only in the presence of lymphokines or cytokines acting as B-cell populations were prepared from spleen cell suspen- B-cell growth and differentiation factors (BGDF), was used as sions by fractionation on FLU-gelatin as described (15-17). the antigenic stimulus. It was found that murine interleukin 1 Adherent FLU-gelatin was removed from the recovered prepared by recombinant DNA technology was an effective, binding cells by collagenase. The binding population is 97% although weak, BGDF when acting with antigen on B cells B cells, -z70% FLU-binding, and -200-fold enriched for in cultured either under filler cell-free conditions or in the vitro reactivity to FLU conjugates (13, 16, 17). presence of3T3 cells. When the murine interleukin 1 was used Antigen. The hapten FLU was coupled onto aminoethyl- in combination with recombinant human interleukin 2, itself a carbonylmethylated Ficoll (AECM53-Ficoll), as described weak but effective BGDF in the system, an additive effect was (16, 17), and the FLU53-Ficoll was used as a final concen- observed. The results challenge the notion that interleukin 1 is tration of 0.1 ng/ml. exclusively or even primarily an activating cytokine. This EL4 Thymoma Cell-Derived BGDF. A lOx concentrate of system, in which pure factors are able to act with specific medium conditioned by concanavalin A-stimulated EL4 antigen on single hapten-specific B cells, will prove helpful for thymoma cells prepared as described (12) was used as a the further dissection of the respective roles of the various source ofT-cell-derived BGDF at a final concentration of5% factors that can act on B cells. (vol/vol). According to the recently proposed convention (18) this is termed EL-BGDF-pik. The important macrophage-derived growth-regulatory mol- Recombinant Murine IL-1 (r-mu-IL-1). The r-mu-IL-1 was ecule interleukin 1 (IL-1) (1) has recently been produced in prepared as described (2) and kindly provided by Hoff- pure form through recombinant DNA technology (2). Ever mann-La Roche (lot 11319-229-48). The concentration of since the description of IL-1 as a lymphocyte-activating r-mu-IL-1 is expressed as units/ml of IL-1 activity as deter- factor (3, 4), its bioactivity has been assumed to relate mined by the providers, using the thymocyte proliferation primarily if not exclusively to early events in the activation assay (19). of a resting, Go, cell. For example, IL-1 is seen as a cofactor Recombinant Human IL-2 (r-hu-IL-2). The r-hu-IL-2 was required for concanavalin A to exert its activating effects on prepared as described (20) and kindly provided by Cetus T lymphocytes (5) with concomitant expression of IL-2 Immune (Palo Alto, CA) (lot LP-222). Activity is expressed receptors, after which IL-2 is seen as the only growth factor as units/ml of r-hu-IL-2 as determined by using a murine required for further proliferation ofthe T-cell clone. IL-1 has CTL-L line as described (21). also been implicated in the activation of B lymphocytes B-Cell Cloning Systems. FLU-specific B cells were cultured (6-10), though in this instance, some work has suggested that in 60-well Terasaki trays at a mean of0.4-12 cells per well in it acts later than another postulated activating factor, B-cell- 10 ,ud of RPMI 1640 medium supplemented with 5% (vol/vol) stimulating factor 1 (BSF-1) (6). fetal calf serum and 100 AM 2-mercaptoethanol, either in the We have reported (11-14) a system in which normal murine absence of any added filler cells or in the presence of 300 B lymphocytes, preselected on the basis of their antigen BALB/c 3T3 fibroblast cells as described (13, 14, 17). For specificity, are able to be stimulated to proliferate and some purposes-e.g., the delineation of factor concentra- differentiate to immunoglobulin secretion status when cul- tion-response characteristics-an oligoclonal approach using tured singly in the presence of antigen and a source of B-cell a mean of 10 B cells per well was used as described (14). The growth and differentiation factors (BGDF). Under these additional presence of filler cells markedly improves both conditions, the B cell itself is the only possible target for the cloning efficiency and clone size (13, 14, 17). Routinely, 300 action of antigen and factors. In the belief that this system 3T3 cells were dispensed into the culture wells in 5 Al of was ideal for testing various purified factors for bioactivity on medium prior to the addition of the B cells to allow time for B cells, we have used it to assess the bioactivity of murine adherence. To avoid intertray variance, B cells are dispensed IL-1, prepared by recombinant DNA technology (r-mu-IL-1). into the wells of all trays in 5 1.d of medium containing twice The results show IL-1 to have a combination ofbioactivities, the required concentration of antigen. For filler cell-free including the promotion ofboth growth and differentiation of B cells. Moreover, when filler cells were added to the single Abbreviations: FLU, fluorescein; AFC, antibody-forming cell; BSF- 1, B-cell-stimulating factor 1; BGDF, B-cell growth and differenti- ation factor(s); BCGF, B-cell growth factor; IL-1 and IL-2, inter- The publication costs ofthis article were defrayed in part by page charge leukin 1 and 2; r-mu-IL-1, recombinant murine IL-1; r-hu-IL-2, payment. This article must therefore be hereby marked "advertisement" recombinant human IL-2; SAM, sheep anti-murine immunoglobulin in accordance with 18 U.S.C. §1734 solely to indicate this fact. antibody. 8153 Downloaded by guest on September 27, 2021 8154 Immunology: Pike and Nossal Proc. Natl. Acad Sci. USA 82 (1985) conditions, a further 5 ul of medium alone was added. Number of B cells per well Factors were added in a further 1 /.l of medium at lix the 0.4 0.6 0.8 1.0 1.2 1 required final concentration. Assessment of Clonal Proliferation. Before assay for anti- body formation, culture wells were examined, by using an inverted phase microscope as described (12, 13, 17), for the presence or absence of a proliferating B-cell clone. In the presence of 3T3 cells, the proliferating B cells could usually be distinguished, due to the adherence to plastic, the different morphology, and the substantially larger size ofthe 3T3 cells. Assessment of Antibody Formation. Antibody formation was assessed by using a sensitive enzyme-linked immuno- sorbent assay (ELISA) procedure as described (14). As the In target B cells were selected for specificity for FLU by a) prefractionation on hapten-gelatin, a sheep anti-murine 0) immunoglobulin antibody (SAM) was used as the polyvalent GJ- antigen in the ELISA assay rather than to FLU coupled cmC bovine serum albumin. This change was to measure antibody a) production per se, regardless of its affinity, as a result of particular stimuli. Briefly, the supernatant fluid of each culture well was individually transferred into the wells of a 96-well flexible U-bottomed polyvinyl plate (Dynatech, Alexandria, VA) precoated with affinity-purified SAM (Silenus Laboratories, Dandenong, Australia) at 3 ,ug/ml and containing 50 /.l of0.3% skim milk powder and 0.05% Tween 20 in phosphate-buffered saline. After a period of >2 hr at room temperature, the plates were washed in PBS-tween 20 and horseradish peroxidase-coupled SAM was added for a period of >4 hr. After washing, the substrate 2,2'-azinobis(3- ethylbenzthiazolinesulfonic acid) (ABTS) (Sigma) was added and the absorbance ofthe fluid in the wells was read 1 hr later with a Titertek Multiscan ML (Flow Laboratories) using dual wavelengths (414 and 492 nm). A well was considered positive if its absorbance exceeded the mean ± 3 SEM of the FIG. 1. Limiting dilution analysis ofthe response ofFLU-specific background as calculated on the basis of a large number of B cells as assessed by AFC clone formation by ELISA. (A) Response replicates of supernatants from wells lacking B-cell input. to FLU-Ficoll and EL-BGDF-pik (x-x) (frequency value, 46.3% ± Control wells lacking antibody consistently gave an absorb- 12.5%). (B) Response to FLU-Ficoll alone (x-x) (frequency value, 2.76% ± 0.6%) or FLU-Ficoll plus r-mu-IL-1 at 100 units/ml (a-0) ance value of <0.010 unit.
Load more

Recommended publications
  • Modulation of Endotoxin-Induced Monokine Release in Human Monocytes by Lipid a Partial Structures That Inhibit Binding of '25I-Lipopolysaccharide
    INFECTION AND IMMUNITY, Dec. 1992, p. 5145-5152 Vol. 60, No. 12 0019-9567/92/125145-08$02.00/0 Copyright © 1992, American Society for Microbiology Modulation of Endotoxin-Induced Monokine Release in Human Monocytes by Lipid A Partial Structures That Inhibit Binding of '25I-Lipopolysaccharide ARTUR J. ULMER,`* WERNER FEIST,' HOLGER HEINE,' TERUO KIRIKAE,2 FUMIKO KIRIKAE,2 SHOICHI KUSUMOTO,3 TSUNEO KUSAMA,4 HELMUT BRADE,2 ULRICH SCHADE,2 ERNST T. RIETSCHEL,2 AND HANS-DIETER FLAD' Department ofImmunology and Cell Biology' and Department ofImmunochemistry and Biochemical Microbiology,2 Forschungsinstitut Borstel, D-2061 Borstel, Gennany, and Department of Chemistry, Osaka University, Osaka, 3 and Daiichi Pharmaceutical Co. Ltd., Tokyo,4 Japan Received 15 June 1992/Accepted 24 September 1992 We have previously shown that the synthetic tetraacyl precursor Ia (compound 406, LA-14-PP, or lipid IVa) was not able to induce the production of tumor necrosis factor, interleukin-1, and interleukin-6 in human monocytes but strongly antagonized lipopolysaccharide (LPS)-induced formation of these monokines. This inhibition was detectable at the level of mRNA production. To achieve a better understanding of molecular basis of this inhibition, we investigated whether lipid A precursor Ia (LA-14-PP), Escherichia coli-type lipid A (LA-15-PP), Chromobacterium violaceum-type lipid A (LA-22-PP), and synthetic lipid A partial structures and analogs (LA-23-PP, LA-24-PP, and PE-4) were able to influence the binding of 125I-LPS to human monocytes and compared this inhibitory activity with the agonistic and antagonistic action in the induction of monokines in human monocytes.
    [Show full text]
  • (TRAIL)-Mediated Apoptosis by Helicobacter Pylori in Immun
    + MODEL Journal of Microbiology, Immunology and Infection (2016) xx,1e6 Available online at www.sciencedirect.com ScienceDirect journal homepage: www.e-jmii.com REVIEW ARTICLE Modulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis by Helicobacter pylori in immune pathogenesis of gastric mucosal damage Hwei-Fang Tsai a,b, Ping-Ning Hsu c,d,* a Department of Internal Medicine, Taipei Medical University Shuang Ho Hospital, Taipei, Taiwan b Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan c Graduate Institute of Immunology, College of Medicine, National Taiwan University, Taipei, Taiwan d Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan Received 1 March 2015; received in revised form 20 December 2015; accepted 17 January 2016 Available online --- KEYWORDS Abstract Helicobacter pylori infection is associated with chronic gastritis, peptic ulcer, apoptosis; gastric carcinoma, and gastric mucosa-associated lymphoid tissue lymphomas. Apoptosis chemokine; induced by microbial infections is implicated in the pathogenesis of H. pylori infection. FLIP; Enhanced gastric epithelial cell apoptosis during H. pylori infection was suggested to play Helicobacter pylori; an important role in the pathogenesis of chronic gastritis and gastric pathology. In addition TRAIL to directly triggering apoptosis, H. pylori induces sensitivity to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in gastric epithelial cells. Human gastric epithelial cells sensitized to H. pylori confer susceptibility to TRAIL-mediated apoptosis via modulation of death-receptor signaling. The induction of TRAIL sensitivity by H. pylori is dependent upon the activation of caspase-8 and its downstream pathway. H. pylori induces caspase-8 activation via enhanced assembly of the TRAIL death-inducing signaling complex through downregulation of cellular FLICE-inhibitory protein.
    [Show full text]
  • Huil36g 169 Data Sheet
    Growth Factor Data Sheet GoldBio growth factors are manufactured for RESEARCH USE ONLY and cannot be sold for human consumption! Interleukin-36G (IL36G) is a pro-inflammatory cytokine that plays an important role in the pathophysiology of several diseases. IL36A, IL36B and IL36G; (formerly IL1F6, IL1F8, and IL1F9) are IL1 family members that signal through the IL1 receptor family members IL1Rrp2 (IL1RL2) and IL1RAcP. IL36B is secreted when transfected into 293-T cells and could constitute part of an independent signaling system analogous to that of IL1A and IL1B receptor agonist and interleukin-1 receptor type I (IL1R1). Furthermore, IL36G also can function as an agonist of NFκB activation through the orphan IL1- receptor-related protein 2. Recombinant human IL36G is synthesized as a protein that contains no signal sequence, no prosegment and no potential N-linked glycosylation site.There is a 53% amino acid homology between human and mouse IL36G. IL36G also has a 25-55% amino acid homology with IL36G and IL1RN, IL1B, IL36RN, IL36A, IL37, IL36B and IL1F10. Catalog Number 1110-36E Product Name IL36G (IL-36 gamma), Human (169 a.a.) Recombinant Human Interleukin-36γ IL36G, IL36γ Interleukin 1 Homolog 1 (IL1H1) Interleukin 1-Related Protein 2 (IL1RP2) Interleukin 1 Family, Member 9 (IL1F9) Source Escherichia coli MW 18.7 kDa (169 amino acids) Sequence MRGTPGDADG GGRAVYQSMC KPITGTINDL NQQVWTLQGQ NLVAVPRSDS VTPVTVAVIT CKYPEALEQG RGDPIYLGIQ NPEMCLYCEK VGEQPTLQLK EQKIMDLYGQ PEPVKPFLFY RAKTGRTSTL ESVAFPDWFI ASSKRDQPII LTSELGKSYN TAFELNIND Accession Number Q9NZH8 Purity >95% by SDS-PAGE and HPLC analyses Biological Activity Fully biologically active when compared to standard. The specific activity is determined by its binding ability in a functional ELISA.
    [Show full text]
  • Interleukin (IL)17A, F and AF in Inflammation: a Study in Collageninduced Arthritis and Rheumatoid Arthritis
    bs_bs_banner Clinical and Experimental Immunology ORIGINAL ARTICLE doi:10.1111/cei.12376 Interleukin (IL)-17A, F and AF in inflammation: a study in collagen-induced arthritis and rheumatoid arthritis S. Sarkar,* S. Justa,* M. Brucks,* Summary J. Endres,† D. A. Fox,† X. Zhou,* Interleukin (IL)-17 plays a critical role in inflammation. Most studies to date F. Alnaimat,* B. Whitaker,‡ have elucidated the inflammatory role of IL-17A, often referred to as IL-17. J. C. Wheeler,‡ B. H. Jones§ and IL-17F is a member of the IL-17 family bearing 50% homology to IL-17A S. R. Bommireddy* and can also be present as heterodimer IL-17AF. This study elucidates the *Section of Rheumatology, Department of Medicine, and the Arizona Arthritis Center, distribution and contribution of IL-17A, F and AF in inflammatory arthritis. University of Arizona, Tucson, AZ, †Divison of Neutralizing antibody to IL-17A alone or IL-17F alone or in combination Rheumatology, Department of Internal Medicine, was utilized in the mouse collagen-induced arthritis (CIA) model to eluci- University of Michigan, Ann Arbor, MI, and date the contribution of each subtype in mediating inflammation. IL-17A, F ‡Biologics Research and §Immunology Discovery and AF were all increased during inflammatory arthritis. Neutralization of Research, Janssen Research and Development, IL-17A reduced the severity of arthritis, neutralization of IL-17A+IL-17F had Spring House, PA, USA the same effect as neutralizing IL-17A, while neutralization of IL-17F had no effect. Moreover, significantly higher levels of IL-17A and IL-17F were detected in peripheral blood mononuclear cells (PBMC) from patients with rheumatoid arthritis (RA) in comparison to patients with osteoarthritis (OA).
    [Show full text]
  • And Α Mediated in Part by Enhanced IL-1 Formation in Spleen-Ost
    1,25 (OH)2 Vitamin D3-Stimulated Osteoclast Formation in Spleen-Osteoblast Cocultures Is Mediated in Part by Enhanced IL-1α and Receptor Activator of NF- κB Ligand This information is current as Production in Osteoblasts of September 28, 2021. Sun-Kyeong Lee, Judy Kalinowski, Sandra Jastrzebski and Joseph A. Lorenzo J Immunol 2002; 169:2374-2380; ; doi: 10.4049/jimmunol.169.5.2374 Downloaded from http://www.jimmunol.org/content/169/5/2374 References This article cites 58 articles, 9 of which you can access for free at: http://www.jimmunol.org/ http://www.jimmunol.org/content/169/5/2374.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on September 28, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2002 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology 1,25 (OH)2 Vitamin D3-Stimulated Osteoclast Formation in Spleen-Osteoblast Cocultures Is Mediated in Part by Enhanced IL-1␣ and Receptor Activator of NF-␬B Ligand Production in Osteoblasts1 Sun-Kyeong Lee,2 Judy Kalinowski, Sandra Jastrzebski, and Joseph A.
    [Show full text]
  • Interleukin 2 Medical Intensive Care Unit (4MICU)
    Interleukin 2 Medical Intensive Care Unit (4MICU) Ronald Reagan UCLA Medical Center 757 Westwood Plaza Los Angeles, CA 90095 Main Phone: (310) 267-7441 Fax: (310) 267-3785 About Our Unit The Medical Intensive Care Unit (MICU) cares Quick for critically ill patients in an intensive care Reference Guide environment, with nursing staff specially trained in the administration of Interleukin 2 therapy. Unit Director / Manager Mark Flitcraft, RN, MSN One registered nurse (RN) is assigned to take (310) 267-9529 care of a maximum of two patients. Our Medical Clinical Nurse Specialist Intensive Care Unit patient rooms are designed Yuhan Kao, RN, MSN, CNS (310) 267-7465 to allow nurses constant visual contact with their patients. As a safety precaution, the Medical Assistant Manager Sherry Xu, RN, BA, CCRN Intensive Care Unit is a closed unit and requires (310) 267-7485 permission to enter by intercom. Clinical Case Manager Each private-patient-care room contains the Connie Lefevre (310) 267-9740 most advanced intensive-care equipment available, including cardiac-monitoring and Clinical Social Worker Codie Lieto emergency-response equipment. The curtains in (310) 267-9741 the room will usually be drawn to keep your room Charge Nurse On-Duty more private. (310) 267-7480 or (310) 267-7482 A brief tour is available on weekdays for patients and visitors interested in walking through the unit Patient Affairs (310) 267-9113 and meeting the staff before arrival. To arrange for a tour, please call the nurse manager at Respiratory Supervisor (310) 267-9529. Orna Molayeme, MA, RCP, RRT, NPS (310) 267-8921 UCLAHEALTH.ORG 1-800-UCLA-MD1 (1-800-825-2631) About Our Unit During Your Stay Quick The Medical Team Reference Guide During each shift, you will be assigned a registered nurse (RN) and a clinical care partner (CCP).
    [Show full text]
  • IL36G Blocking Peptide (CDBP5559) This Product Is for Research Use Only and Is Not Intended for Diagnostic Use
    IL36G blocking peptide (CDBP5559) This product is for research use only and is not intended for diagnostic use. PRODUCT INFORMATION Antigen Description The protein encoded by this gene is a member of the interleukin 1 cytokine family. The activity of this cytokine is mediated by interleukin 1 receptor-like 2 (IL1RL2/IL1R-rp2), and is specifically inhibited by interleukin 1 family, member 5 (IL1F5/IL-1 delta). Interferon-gamma, tumor necrosis factor-alpha and interleukin 1, beta (IL1B) are reported to stimulate the expression of this cytokine in keratinocytes. The expression of this cytokine in keratinocytes can also be induced by a contact hypersensitivity reaction or herpes simplex virus infection. This gene and eight other interleukin 1 family genes form a cytokine gene cluster on chromosome 2. Two alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jun 2013] Immunogen 13 amino acids near the carboxy terminus of human IL-36G. Nature Synthetic Expression System N/A Species Reactivity Human Conjugate Unconjugated Applications Used as a blocking peptide in immunoblotting applications. Procedure None Format Liquid Concentration 200 μg/mL Size 0.05mg Preservative None Storage -20°C ANTIGEN GENE INFORMATION Gene Name IL36G interleukin 36, gamma [ Homo sapiens (human) ] Official Symbol IL36G 45-1 Ramsey Road, Shirley, NY 11967, USA Email: [email protected] Tel: 1-631-624-4882 Fax: 1-631-938-8221 1 © Creative Diagnostics All Rights Reserved Synonyms IL36G; interleukin
    [Show full text]
  • TSLP-Activated Dendritic Cells Induce an Inflammatory T Helper Type 2 Cell
    ARTICLE TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through OX40 ligand Tomoki Ito,1 Yui-Hsi Wang,1 Omar Duramad,1,2 Toshiyuki Hori,3 Guy J. Delespesse,4 Norihiko Watanabe,1 F. Xiao-Feng Qin,1 Zhengbin Yao,5 Wei Cao,1 and Yong-Jun Liu1,2 1Center for Cancer Immunology Research, Department of Immunology, The University of Texas M.D. Anderson Cancer Center, and 2The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, TX 77030 3Department of Hematology/Oncology, Graduate School of Medicine, Kyoto University, Sakyo-ku, Kyoto 606-8507, Japan 4Allergy Research Laboratory, Research Center of Centre Hospitalier Université de Montreal, Notre Dame Hospital, Montreal, Quebec H2L 4M1, Canada 5Tanox, Inc., Houston, TX 77025 We recently showed that dendritic cells (DCs) activated by thymic stromal lymphopoietin Downloaded from TSLP) prime naive CD4؉ T cells to differentiate into T helper type 2 (Th2) cells that) produced high amounts of tumor necrosis factor-␣ (TNF-␣), but no interleukin (IL)-10. Here we report that TSLP induced human DCs to express OX40 ligand (OX40L) but not IL-12. TSLP-induced OX40L on DCs was required for triggering naive CD4؉ T cells to produce IL-4, -5, and -13. We further revealed the following three novel functional properties of OX40L: (a) OX40L selectively promoted TNF-␣, but inhibited IL-10 production jem.rupress.org in developing Th2 cells; (b) OX40L lost the ability to polarize Th2 cells in the presence of IL-12; and (c) OX40L exacerbated IL-12–induced Th1 cell inflammation by promoting TNF-␣, while inhibiting IL-10.
    [Show full text]
  • Growth Factor Data Sheet
    Growth Factor Data Sheet GoldBio growth factors are manufactured for RESEARCH USE ONLY and cannot be sold for human consumption! Interleukin 36B (IL36B) is a pro-inflammatory cytokine which plays an important role in the pathophysiology of several diseases. IL36A, IL36B, and IL36G (formerly IL1F6, IL1F8, and IL1F9) are all IL1 family members that signal through the IL1 receptor family members IL1Rrp2 (IL1RL2) and IL1RAcP. IL36B is reported to be expressed at higher levels in psoriatic plaques than in symptomless psoriatic skin or healthy control skin. IL36B can also stimulate the production of IL6 and IL8 in synovial fibroblasts, articular chondrocytes and mature adipocytes. Catalog Number 1310-36D Product Name IL36B (IL-36 beta), Murine (153 a.a.) Recombinant Murine Interleukin-36β IL36B, IL36β Interleukin 36β Interleukin 1 Family, Member 8 (IL1F8) Source Escherichia coli MW ~17.4 kDa (153 amino acids) Sequence RAASPSLRHV QDLSSRVWIL QNNILTAVPR KEQTVPVTIT LLPCQYLDTL ETNRGDPTYM GVQRPMSCLF CTKDGEQPVL QLGEGNIMEM YNKKEPVKAS LFYHKKSGTT STFESAAFPG WFIAVCSKGS CPLILTQELG EIFITDFEMI VVH Purity >95% by SDS-PAGE and HPLC analyses Biological Activity Fully biologically active when compared to standard. The ED50 as determined by inducing IL-6 secretion in murine NIH/3T3 cells is less than 25 ng/ml, corresponding to a specific activity of >4.0 × 104 IU/mg. Formulation Sterile filtered white lyophilized powder. Purified and tested for use in cell culture. Storage/Handling This lyophilized preparation is stable at 2-8°C, but should be kept at -20°C for long term storage. The reconstituted sample can be apportioned into working aliquots and stored at -80 °C for up to 6 months.
    [Show full text]
  • The Role of Interleukin-1 Cytokine Family (IL-1Β, IL-37) and Interleukin-12 Cytokine
    bioRxiv preprint doi: https://doi.org/10.1101/502609; this version posted December 22, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. 1 Title: 2 The Role of Interleukin-1 cytokine family (IL-1β, IL-37) and interleukin-12 cytokine 3 family (IL-12, IL-35) in eumycetoma infection pathogenesis. 4 5 6 Authors 7 Amir Abushouk1,2, Amre Nasr1,2,3, Emad Masuadi4, Gamal Allam5,6, Emmanuel E. Siddig7, 8 Ahmed H. Fahal7 9 10 1Department of Basic Medical Sciences, College of Medicine, King Saud Bin Abdul-Aziz 11 University for Health Sciences, Jeddah, Kingdom of Saudi Arabia. E. mail: shouka@ksau- 12 hs.edu.sa 13 14 2King Abdullah International Medical Research Centre, National Guard Health Affairs, 15 Kingdom of Saudi Arabia. 16 17 3Department of Microbiology, College of Sciences and Technology, Al-Neelain University, 18 P.O. Box 1027, Khartoum, Sudan. [email protected] 19 20 4Research Unit, Department of Medical Education, College of Medicine-Riyadh, King Saud 21 Bin Abdul-Aziz University for Health Sciences, Riyadh, Kingdom of Saudi Arabia. E. mail: 22 [email protected] 23 bioRxiv preprint doi: https://doi.org/10.1101/502609; this version posted December 22, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
    [Show full text]
  • A Novel CD4+ CTL Subtype Characterized by Chemotaxis and Inflammation Is Involved in the Pathogenesis of Graves’ Orbitopa
    Cellular & Molecular Immunology www.nature.com/cmi ARTICLE OPEN A novel CD4+ CTL subtype characterized by chemotaxis and inflammation is involved in the pathogenesis of Graves’ orbitopathy Yue Wang1,2,3,4, Ziyi Chen 1, Tingjie Wang1,2, Hui Guo1, Yufeng Liu2,3,5, Ningxin Dang3, Shiqian Hu1, Liping Wu1, Chengsheng Zhang4,6,KaiYe2,3,7 and Bingyin Shi1 Graves’ orbitopathy (GO), the most severe manifestation of Graves’ hyperthyroidism (GH), is an autoimmune-mediated inflammatory disorder, and treatments often exhibit a low efficacy. CD4+ T cells have been reported to play vital roles in GO progression. To explore the pathogenic CD4+ T cell types that drive GO progression, we applied single-cell RNA sequencing (scRNA-Seq), T cell receptor sequencing (TCR-Seq), flow cytometry, immunofluorescence and mixed lymphocyte reaction (MLR) assays to evaluate CD4+ T cells from GO and GH patients. scRNA-Seq revealed the novel GO-specific cell type CD4+ cytotoxic T lymphocytes (CTLs), which are characterized by chemotactic and inflammatory features. The clonal expansion of this CD4+ CTL population, as demonstrated by TCR-Seq, along with their strong cytotoxic response to autoantigens, localization in orbital sites, and potential relationship with disease relapse provide strong evidence for the pathogenic roles of GZMB and IFN-γ-secreting CD4+ CTLs in GO. Therefore, cytotoxic pathways may become potential therapeutic targets for GO. 1234567890();,: Keywords: Graves’ orbitopathy; single-cell RNA sequencing; CD4+ cytotoxic T lymphocytes Cellular & Molecular Immunology
    [Show full text]
  • Evolutionary Divergence and Functions of the Human Interleukin (IL) Gene Family Chad Brocker,1 David Thompson,2 Akiko Matsumoto,1 Daniel W
    UPDATE ON GENE COMPLETIONS AND ANNOTATIONS Evolutionary divergence and functions of the human interleukin (IL) gene family Chad Brocker,1 David Thompson,2 Akiko Matsumoto,1 Daniel W. Nebert3* and Vasilis Vasiliou1 1Molecular Toxicology and Environmental Health Sciences Program, Department of Pharmaceutical Sciences, University of Colorado Denver, Aurora, CO 80045, USA 2Department of Clinical Pharmacy, University of Colorado Denver, Aurora, CO 80045, USA 3Department of Environmental Health and Center for Environmental Genetics (CEG), University of Cincinnati Medical Center, Cincinnati, OH 45267–0056, USA *Correspondence to: Tel: þ1 513 821 4664; Fax: þ1 513 558 0925; E-mail: [email protected]; [email protected] Date received (in revised form): 22nd September 2010 Abstract Cytokines play a very important role in nearly all aspects of inflammation and immunity. The term ‘interleukin’ (IL) has been used to describe a group of cytokines with complex immunomodulatory functions — including cell proliferation, maturation, migration and adhesion. These cytokines also play an important role in immune cell differentiation and activation. Determining the exact function of a particular cytokine is complicated by the influence of the producing cell type, the responding cell type and the phase of the immune response. ILs can also have pro- and anti-inflammatory effects, further complicating their characterisation. These molecules are under constant pressure to evolve due to continual competition between the host’s immune system and infecting organisms; as such, ILs have undergone significant evolution. This has resulted in little amino acid conservation between orthologous proteins, which further complicates the gene family organisation. Within the literature there are a number of overlapping nomenclature and classification systems derived from biological function, receptor-binding properties and originating cell type.
    [Show full text]